Topical azithromycin or ofloxacin for endophthalmitis
Authors Stewart M, Stewart L
Received 16 October 2012
Accepted for publication 16 October 2012
Published 31 December 2012 Volume 2013:7 Pages 35—38
Michael W Stewart, Michael L Stewart
Department of Ophthalmology, Mayo Clinic, Jacksonville, FL, USA
The recently published study by Romero-Aroca et al1 raises interesting questions regarding the effect of choice of topical antibiotic (azithromycin versus ofloxacin) on the incidence of endophthalmitis following intravitreal injections. However, important conclusions advanced by the authors deserve further discussion. First, the authors state that use of azithromycin leads to significantly fewer cases of post-injection endophthalmitis than does the use of ofloxacin. Their prospective series shows a lower endophthalmitis rate in eyes treated with azithromycin (two cases in 4045 injections, 0.049%) than in eyes treated with ofloxacin (five cases in 4151 injections, 0.12%). They calculate a relative risk of 2.37, and conclude that this was statistically significant (confidence interval 1.37–3.72; P < 0.001).
View original paper by Romero-Aroca and colleagues.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]